Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears
New York, January 5, 2026, 5:47 PM ET — After-hours Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States. The Washington Post The drop matters because investors have priced Lilly as a long-duration obesity winner, with expectations anchored to rapid growth in demand and tight supply. Any new sign that the market is shifting toward cheaper oral options can force a reset in assumptions about pricing power. GLP-1 drugs,